{
    "clinical_study": {
        "@rank": "66981", 
        "acronym": "RAPID", 
        "arm_group": [
            {
                "arm_group_label": "sertraline + riluzole", 
                "arm_group_type": "Experimental", 
                "description": "sertraline 100 mg po daily and riluzole 50 mg po bid"
            }, 
            {
                "arm_group_label": "sertraline + placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "sertraline 100 mg po daily and placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The investigators are doing a research study to find out if riluzole, when taken along with\n      a standard antidepressant (sertraline) can help people with major depression.\n\n      This research study will compare riluzole + sertraline to placebo + sertraline. The\n      investigators hypothesize that adding riluzole will lead to a better antidepressant\n      response, in less time, then sertraline alone."
        }, 
        "brief_title": "Riluzole Augmentation Pilot in Depression (RAPID) Trial", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Depressive Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Depression", 
                "Depressive Disorder", 
                "Depressive Disorder, Major"
            ]
        }, 
        "detailed_description": {
            "textblock": "Recent attention has focused on the glutamatergic system as a new, distinct target for\n      depression treatment. Riluzole (Rilutek, Sanofi), an oral modulator of glutamate activity\n      with neuroprotective and anticonvulsant properties, is currently approved by the United\n      States Food and Drug Administration for treatment of amyotrophic lateral sclerosis (ALS).\n      Preliminary studies using riluzole to treat depression in humans are promising, though\n      larger, double-blinded controlled trials are needed.\n\n      Overall study population:\n\n      Adult outpatients with a current, untreated major depressive episode.\n\n      Disallowed therapies include: other psychotropic medications, including antipsychotics, mood\n      stabilizers, benzodiazepines, barbiturates, other sedative-hypnotics, chronic opiates, or\n      additional antidepressants, psychotherapy, electroconvulsive therapy, vagal nerve\n      stimulations therapy, transcranial magnetic stimulation therapy, or phototherapy."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adults (ages 18-75) who meet DSM-IV criteria for a major depressive episode,\n\n          -  Hamilton Depression Rating Scale (HDRS) >22, and\n\n          -  No antidepressant treatment for at least three weeks\n\n        Exclusion Criteria:\n\n          -  Active drug or alcohol disorder in the past 3 months\n\n          -  History of psychosis, history of mania or hypomania\n\n          -  Epilepsy or history of seizures\n\n          -  Hypothyroidism\n\n          -  Congenital QTc prolongation\n\n          -  Liver disease\n\n          -  Lung disease\n\n          -  Acute suicide or homicide risk\n\n          -  Pregnant women, breastfeeding women, women of childbearing age not using\n             contraception\n\n          -  Unstable medical illness\n\n          -  Elevated thyroid-stimulating hormone (TSH>5.0mlU/L), or\n\n          -  Abnormal liver function tests (ALT>50 U/L or AST>50 U/L)\n\n        Disallowed therapies include: other psychotropic medications, including antipsychotics,\n        mood stabilizers, benzodiazepines, barbiturates, other sedative-hypnotics, chronic\n        opiates, or additional antidepressants, psychotherapy, electroconvulsive therapy, vagal\n        nerve stimulations therapy, transcranial magnetic stimulation therapy, or phototherapy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "42", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703039", 
            "org_study_id": "2012P001841"
        }, 
        "intervention": [
            {
                "arm_group_label": "sertraline + riluzole", 
                "intervention_name": "Riluzole", 
                "intervention_type": "Drug", 
                "other_name": "Rilutek"
            }, 
            {
                "arm_group_label": [
                    "sertraline + riluzole", 
                    "sertraline + placebo"
                ], 
                "intervention_name": "Sertraline", 
                "intervention_type": "Drug", 
                "other_name": "Zoloft"
            }, 
            {
                "arm_group_label": "sertraline + placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Riluzole", 
                "Sertraline"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Major Depression", 
            "Major Depressive Disorder", 
            "Depression", 
            "Riluzole", 
            "Glutamate", 
            "Sertraline"
        ], 
        "lastchanged_date": "July 29, 2013", 
        "location": {
            "contact": {
                "email": "SLAHIRI@PARTNERS.ORG", 
                "last_name": "Sutanuka Lahiri, MS"
            }, 
            "contact_backup": {
                "email": "DWOLFE@PARTNERS.ORG", 
                "last_name": "David Wolfe, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02115"
                }, 
                "name": "Brigham and Women's Hospital"
            }, 
            "investigator": {
                "last_name": "David J Wolfe, MD, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Riluzole Augmentation Pilot in Depression (RAPID) Trial", 
        "overall_contact": {
            "email": "DWOLFE@PARTNERS.ORG", 
            "last_name": "David J Wolfe, MD", 
            "phone": "617-525-8806"
        }, 
        "overall_official": {
            "affiliation": "Brigham and Women's Hospital", 
            "last_name": "David J Wolfe, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Mean change in Hamilton Depression Rating Scale (HDRS) score from baseline to endpoint at 8 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Proportion of patients experiencing an antidepressant response (>50% reduction in HDRS) at endpoint of 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Proportion of patients experiencing remission from depression (HDRS<7) at endpoint of 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703039"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Brigham and Women's Hospital", 
            "investigator_full_name": "David John Wolfe", 
            "investigator_title": "Physician", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean change in Hamilton Anxiety Rating Scale (HARS) score from baseline to endpoint at 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Mean change in Clinical Global Impression (CGI) scale from baseline to endpoint at 8 weeks", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Brigham and Women's Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Brigham and Women's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}